Found 2 articles for: "Apremilast"
The Maintenance Effect of Calcipotriene 0.05% and Betamethasone Dipropionate 0.064% (Cal/BD) Aerosol Foam in Combination With Apremilast
April 2022 | Volume 21 | Issue 4 | Original Article | 381 | Copyright © April 2022
Even in light of significant recent therapeutic advancements, many patients with psoriasis will use a combination of treatments at some point in the disease course. Despite the frequency with which co...
Read MoreReview of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis
August 2021 | Volume 20 | Issue 8 | Original Article | 837 | Copyright © August 2021
Psoriasis is a chronic inflammatory skin condition resulting from the dysregulation of cytokines. Apremilast, an oral phosphodiesterase-4 inhibitor is approved by the Federal Drug Administration (FDA)...
Read More
